Abstract
BackgroundDespite unprecedented clinical success of CAR T cell therapy against B cell malignancies, its widespread application is limited by lengthy (~4 weeks) and labor intensive ex vivo manufacturing procedures that...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
